This information was published on 2025-10-13T09:37:29 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2593035 |
| (220) |
08 Oct 2025
|
| (300) |
US, 11 Apr 2025, 99132908
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; antivirals; antibodies for medical purposes; biological preparations for the treatment of cancer; anticoagulants; stem cells for medical purposes; radio-pharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radio-pharmaceutical preparations; diagnostic preparations for medical purposes. |
| (540) | VEYATLOS |
| (550) | Word |
| (730) |
Juno Therapeutics, Inc.
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.